Could Tysabri PML Be Missed? Key Warning Signs for Pennsylvania Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Risk Awareness

If you or a loved one is taking Tysabri, recognizing the earliest signs of progressive multifocal leukoencephalopathy (PML) can be life-saving. Subtle symptoms like confusion, vision changes, or limb weakness are often mistaken for other conditions. The medical community has long emphasized that timely diagnosis of PML hinges on awareness of these clinical red flags. This page outlines the key warning signs and risk factors every patient and caregiver should know.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe and often fatal brain infection caused by the JC virus (JCV). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, specifically addressing this risk. The warning states that "TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence and post-marketing surveillance data. PML is a demyelinating disease of the central nervous system. It is caused by the JC polyomavirus, which typically remains latent in healthy individuals but can reactivate in those with compromised immune systems. A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 described PML as "a severe demyelinating disease caused by JC polyomavirus (JCV), affecting immunocompromised individuals" (https://pubmed.ncbi.nlm.nih.gov/40922664/). The clinical presentation of PML can vary but often includes progressive neurological deficits such as weakness, cognitive impairment, gait disturbance, and visual changes. Diagnosis typically relies on brain MRI findings and detection of JCV DNA in cerebrospinal fluid.

Mechanism of Risk and FDA-Identified Factors

The mechanistic link between Tysabri and PML is rooted in the drug's pharmacology. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This action reduces inflammation in the central nervous system, which is beneficial for treating multiple sclerosis, but it also impairs immune surveillance within the brain. This impairment allows the JC virus to reactivate and proliferate unchecked, leading to PML. The FDA label identifies three specific risk factors for PML in Tysabri-treated patients: "The presence of anti-JCV antibodies," "longer treatment duration, especially beyond 2 years," and "prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The FDA Adverse Event Reporting System (FAERS) database contains numerous reports of adverse events associated with Tysabri. While the most frequently reported events include fatigue, multiple sclerosis relapse, and headache, the database also captures serious neurological events consistent with PML, such as gait disturbance, balance disorder, cognitive disorder, and muscular weakness (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of vigilant monitoring for any new or worsening neurological symptoms in patients receiving Tysabri.

Adequacy of Warnings and Monitoring Programs

The adequacy of warnings regarding Tysabri and PML is a critical consideration. The FDA requires a boxed warning, and the label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which is designed to educate prescribers and patients about the risk of PML and to ensure appropriate monitoring. Despite these measures, questions may arise about whether patients and healthcare providers were adequately informed about the magnitude and timing of the risk, particularly in cases where PML developed after prolonged therapy. For patients who develop PML after Tysabri exposure, the timeline between exposure and documented harm is a key factor. The risk of PML increases with longer treatment duration, especially beyond two years. The FDA label notes that "longer treatment duration, especially beyond 2 years" is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This means that patients who have been on Tysabri for extended periods may be at higher risk, and the onset of PML symptoms can occur months or years after starting therapy. Early recognition of PML is crucial because prompt discontinuation of Tysabri and initiation of supportive care may improve outcomes, though the prognosis remains poor, with the FDA warning stating that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Affected Patients

Attorney-related considerations for affected patients involve evaluating whether the risks of PML were adequately communicated and whether the patient's specific risk factors were properly assessed before and during treatment. Patients who develop PML may face substantial medical costs, long-term disability, and loss of quality of life. Legal claims could focus on failure to warn, inadequate monitoring, or failure to promptly diagnose PML. The restricted distribution program and boxed warning provide a framework for risk management, but individual circumstances may vary. Patients and their families should consult with legal professionals experienced in pharmaceutical injury cases to understand their rights and options. In summary, Tysabri is associated with a significant risk of PML, a severe brain infection that can lead to death or permanent disability. The FDA has mandated a boxed warning and a restricted distribution program to mitigate this risk, but cases of PML continue to occur, particularly in patients with anti-JCV antibodies, prolonged treatment duration, or prior immunosuppressant use. For those affected, understanding the clinical presentation, risk factors, and legal considerations is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell entry into the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

The FDA identifies three key risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options do patients have if they develop PML after Tysabri?

Patients may pursue claims for failure to warn, inadequate monitoring, or delayed diagnosis. Consulting an attorney experienced in pharmaceutical injury is recommended to evaluate individual circumstances and potential compensation for medical costs and disability.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.